TLR3 and breast cancer: For antitumor immunity, the co-loading of Toll-like receptor 3 (TLR3) agonist Hiltonol, a double-stranded RNA that also acts as an immune adjuvant, and the ICD inducer neutrophil elastase (ELANE) into EVs expressing α-lactalbumin (α-LA) by electroporation (HELA-Exos), can be designed as an antitumor vaccine for breast cancer treatment to achieve in situ activation of DCs.